Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome

[1]  E. Desoky.  Drug therapy of heart failure: an immunologic view. , 2011 .

[2]  S. Ogawa,et al.  Increased C-reactive protein expression exacerbates left ventricular dysfunction and remodeling after myocardial infarction. , 2010, American journal of physiology. Heart and circulatory physiology.

[3]  A. Cass.  Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. , 2010, American heart journal.

[4]  J. Scholz,et al.  Interleukin-1beta regulates cell proliferation and activity of extracellular matrix remodelling enzymes in cultured primary pig heart cells. , 2010, Biochemical and biophysical research communications.

[5]  D. J. Veldhuisen,et al.  Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality , 2010, European journal of heart failure.

[6]  Noel R. Rose,et al.  Proinflammatory cytokines in heart failure: double-edged swords , 2010, Heart Failure Reviews.

[7]  C. Lau,et al.  C-Reactive Protein Promotes Cardiac Fibrosis and Inflammation in Angiotensin II-Induced Hypertensive Cardiac Disease , 2010, Hypertension.

[8]  S. Harrison,et al.  TNF-α and IL-1β increase Ca2+ leak from the sarcoplasmic reticulum and susceptibility to arrhythmia in rat ventricular myocytes , 2010, Cell calcium.

[9]  O. Hammarsten,et al.  Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio , 2010, Clinical Research in Cardiology.

[10]  Z. Massy,et al.  Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. , 2010, Kidney international.

[11]  G. Ertas,et al.  Elevated level of high-sensitivity C-reactive protein is important in determining prognosis in chronic heart failure. , 2010, Medical science monitor : international medical journal of experimental and clinical research.

[12]  C. Longhini,et al.  Cardiorenal syndrome: still not a defined entity , 2010, Clinical and Experimental Nephrology.

[13]  C. Zoccali,et al.  Soluble E-Selectin Is an Inverse and Independent Predictor of Left Ventricular Wall Thickness in End-Stage Renal Disease Patients , 2009, Nephron Clinical Practice.

[14]  S. Anker,et al.  Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. , 2009, Heart failure clinics.

[15]  H. Nonoguchi,et al.  Interleukin-6 Is a Predictor of Mortality in Stable Hemodialysis Patients , 2009, American Journal of Nephrology.

[16]  D. Silverstein.  Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease , 2009, Pediatric Nephrology.

[17]  O. Ortega,et al.  Strict Volume Control and Longitudinal Changes in Cardiac Biomarker Levels in Hemodialysis Patients , 2009, Nephron Clinical Practice.

[18]  H. Sabbah,et al.  Activation of endothelial cells in conduit veins of dogs with heart failure and veins of normal dogs after vascular stretch by acute volume loading. , 2009, Journal of cardiac failure.

[19]  T. Baudino,et al.  IL-6 loss causes ventricular dysfunction, fibrosis, reduced capillary density, and dramatically alters the cell populations of the developing and adult heart. , 2009, American journal of physiology. Heart and circulatory physiology.

[20]  Mohit M. Jain,et al.  A Novel Role for Tumor Necrosis Factor–Like Weak Inducer of Apoptosis (TWEAK) in the Development of Cardiac Dysfunction and Failure , 2009, Circulation.

[21]  Anita K. Sharma,et al.  IL-10 attenuates TNF-alpha-induced NF kappaB pathway activation and cardiomyocyte apoptosis. , 2009, Cardiovascular research.

[22]  A. Ferreira,et al.  Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. , 2009, Journal of cardiac failure.

[23]  G. Navis,et al.  Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. , 2009, Journal of the American College of Cardiology.

[24]  M. Jessup,et al.  The cardiorenal syndrome: do we need a change of strategy or a change of tactics? , 2009, Journal of the American College of Cardiology.

[25]  S. Tyagi,et al.  Tumor Necrosis Factor-related Weak Inducer of Apoptosis Augments Matrix Metalloproteinase 9 (MMP-9) Production in Skeletal Muscle through the Activation of Nuclear Factor-κB-inducing Kinase and p38 Mitogen-activated Protein Kinase , 2009, Journal of Biological Chemistry.

[26]  P. Ponikowski,et al.  Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology , 2009, European journal of heart failure.

[27]  I. Piña,et al.  BNP-guided therapy for heart failure. , 2009, JAMA.

[28]  G. Lip,et al.  Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure , 2009, Annals of medicine.

[29]  Le Wang,et al.  Prednisone adding to usual care treatment for refractory decompensated congestive heart failure. , 2008, International heart journal.

[30]  J. Sur,et al.  Effects of T Lymphocytes, Interleukin-1, and Interleukin-6 on Renal Fibrosis in Canine End-Stage Renal Disease , 2008, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[31]  J. Killian,et al.  Tumor Necrosis Factor-&agr; and Mortality in Heart Failure: A Community Study , 2008, Circulation.

[32]  J. Koyama,et al.  Immunoadsorption Therapy for Patients with Dilated Cardiomyopathy and Heart Failure , 2008, Current cardiology reviews.

[33]  W. Mullens,et al.  Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. , 2008, Journal of the American College of Cardiology.

[34]  T. Hornemann,et al.  In critically ill patients, B-type natriuretic peptide (BNP) and N-terminal pro-BNP levels correlate with C-reactive protein values and leukocyte counts. , 2008, International journal of cardiology.

[35]  G. Lip,et al.  Biomarkers of endothelial dysfunction are elevated and related to prognosis in chronic heart failure patients with diabetes but not in those without diabetes , 2008, European journal of heart failure.

[36]  R. Maas,et al.  Rapid development of severe end-organ damage in C57BL/6 mice by combining DOCA salt and angiotensin II. , 2008, Kidney international.

[37]  B. C. Kwan,et al.  Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[38]  P. Ponikowski,et al.  Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial , 2008, The Lancet.

[39]  L. Belo,et al.  Inflammation, T-Cell Phenotype, and Inflammatory Cytokines in Chronic Kidney Disease Patients Under Hemodialysis and its Relationship to Resistance to Recombinant Human Erythropoietin Therapy , 2008, Journal of Clinical Immunology.

[40]  A. Jánosi,et al.  Rosuvastatin in older patients with systolic heart failure. , 2007, The New England journal of medicine.

[41]  Zhezhen Jin,et al.  Vascular endothelial sampling and analysis of gene transcripts: a new quantitative approach to monitor vascular inflammation. , 2007, Journal of applied physiology.

[42]  Michael D. Schneider,et al.  TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. , 2007, The Journal of clinical investigation.

[43]  D. J. Veldhuisen,et al.  Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction , 2007, European journal of heart failure.

[44]  I. Feavers,et al.  ROLE OF BACTERIAL ENDOTOXIN IN CHRONIC HEART FAILURE: THE GUT OF THE MATTER , 2007, Shock.

[45]  You-Sun Kim,et al.  TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. , 2007, Molecular cell.

[46]  J. Rouleau,et al.  A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design. , 2007, The Canadian journal of cardiology.

[47]  L. Dworkin,et al.  Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. , 2007, Journal of the American Society of Nephrology : JASN.

[48]  V. Cachofeiro,et al.  Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. , 2006, Journal of the American Society of Nephrology : JASN.

[49]  Anita K. Sharma,et al.  Interplay of TNF-α and IL-10 in regulating oxidative stress in isolated adult cardiac myocytes , 2006 .

[50]  H. Drexler,et al.  Molecular Mechanisms in Heart Failure: Focus on Cardiac Hypertrophy, Inflammation, Angiogenesis, and Apoptosis , 2006 .

[51]  R. Pecoits-Filho,et al.  Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[52]  S. Frøland,et al.  The role of intravenous immunoglobulin in the treatment of chronic heart failure. , 2006, International journal of cardiology.

[53]  Jie Shen,et al.  Matrix metalloproteinase-2 contributes to tumor necrosis factor alpha induced apoptosis in cultured rat cardiac myocytes. , 2006, Biochemical and biophysical research communications.

[54]  T. Hornemann,et al.  Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure* , 2006, Critical care medicine.

[55]  J. Rouleau,et al.  Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. , 2006, Clinical science.

[56]  N. Vaziri,et al.  Skeletal muscle dysfunction in chronic renal failure: effects of exercise. , 2006, American journal of physiology. Renal physiology.

[57]  Sanjiv J. Shah,et al.  High-sensitivity C-reactive protein and parameters of left ventricular dysfunction. , 2006, Journal of cardiac failure.

[58]  K. Okumura,et al.  C-reactive protein-induced upregulation of extracellular matrix metalloproteinase inducer in macrophages: inhibitory effect of fluvastatin. , 2006, Life sciences.

[59]  G. Keren,et al.  Usefulness of anti‐oxidized LDL antibody determination for assessment of clinical control in patients with heart failure , 2006, European journal of heart failure.

[60]  C. Stehouwer,et al.  Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. , 2005, Kidney international.

[61]  C. Vlachopoulos,et al.  Acute Systemic Inflammation Increases Arterial Stiffness and Decreases Wave Reflections in Healthy Individuals , 2005, Circulation.

[62]  S. Ogawa,et al.  Interleukin-6/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis , 2005, Laboratory Investigation.

[63]  J. McMurray,et al.  A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics , 2005, European journal of heart failure.

[64]  Gerasimos Filippatos,et al.  Pathophysiologic targets in the early phase of acute heart failure syndromes. , 2005, The American journal of cardiology.

[65]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[66]  M. Fiatarone Singh,et al.  Exercise Training in Patients Receiving Maintenance Hemodialysis: A Systematic Review of Clinical Trials , 2005, American Journal of Nephrology.

[67]  Seung Hun Lee,et al.  Persistent Elevation of C-Reactive Protein May Predict Cardiac Hypertrophy and Dysfunction in Patients Maintained on Hemodialysis , 2005, American Journal of Nephrology.

[68]  G. Smith,et al.  Endothelial Dysfunction in Childhood Infection , 2005, Circulation.

[69]  P. Stenvinkel,et al.  IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. , 2005, Kidney international.

[70]  C. Zoccali,et al.  Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. , 2005, Journal of the American Society of Nephrology : JASN.

[71]  T. LeJemtel,et al.  Endothelial Cell Activation in Patients With Decompensated Heart Failure , 2005, Circulation.

[72]  A. Cohen-Solal,et al.  Evidence for altered interleukin (IL)‐18 pathway in human heart failure , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[73]  D. Mann,et al.  Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression. , 2004, American journal of physiology. Heart and circulatory physiology.

[74]  E. Fleck,et al.  C-Reactive Protein Induces Apoptosis in Human Coronary Vascular Smooth Muscle Cells , 2004, Circulation.

[75]  O. Ortega,et al.  Association between C-Reactive Protein Levels and N-Terminal Pro-B-Type Natriuretic Peptide in Pre-Dialysis Patients , 2004, Nephron Clinical Practice.

[76]  Seung‐Jung Park,et al.  C-Reactive Protein Promotes Monocyte Chemoattractant Protein-1–Mediated Chemotaxis Through Upregulating CC Chemokine Receptor 2 Expression in Human Monocytes , 2004, Circulation.

[77]  J. McMurray,et al.  Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.

[78]  M. Piepoli,et al.  Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH) , 2004, BMJ : British Medical Journal.

[79]  R. Turner,et al.  Interleukin-1 and Nitric Oxide Increase NADPH Oxidase Activity in Human Coronary Artery Smooth Muscle Cells , 2003, Medical Principles and Practice.

[80]  R. Garg,et al.  Angiotensin II and Inflammation: The Effect of ACE Inhibition and Angiotensin II Receptor Blockade. , 2003, Metabolic syndrome and related disorders.

[81]  C. Wanner,et al.  Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[82]  H. Ikeda,et al.  Statins for heart failure: a potential for new treatment. , 2003, Cardiovascular research.

[83]  J. Garvin,et al.  The role of reactive oxygen species in the regulation of tubular function. , 2003, Acta physiologica Scandinavica.

[84]  G. Schuler,et al.  Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure , 2003, European journal of heart failure.

[85]  Bao-Wei Wang,et al.  Induction of matrix metalloproteinases-14 and -2 by cyclical mechanical stretch is mediated by tumor necrosis factor-α in cultured human umbilical vein endothelial cells , 2003 .

[86]  Shing‐Jong Lin,et al.  The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure , 2003, European journal of heart failure.

[87]  C. Herzog,et al.  Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. , 2003, JAMA.

[88]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[89]  S. Anker,et al.  How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. , 2002, International journal of cardiology.

[90]  Marta Ruiz-Ortega,et al.  Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. , 2002, Kidney international. Supplement.

[91]  D. Brutsaert,et al.  Combined endurance/resistance training reduces plasma TNF-alpha receptor levels in patients with chronic heart failure and coronary artery disease. , 2002, European heart journal.

[92]  K. Naruse,et al.  Mechanical stress-dependent secretion of interleukin 6 by endothelial cells after portal vein embolization: clinical and experimental studies. , 2002, Journal of hepatology.

[93]  J. Rouleau,et al.  Subacute and Chronic Effects of Quinapril on Cardiac Cytokine Expression, Remodeling, and Function After Myocardial Infarction in the Rat , 2002, Journal of cardiovascular pharmacology.

[94]  J. Alonso-Martínez,et al.  C‐reactive protein as a predictor of improvement and readmission in heart failure , 2002, European journal of heart failure.

[95]  Z. Vered,et al.  Acute heart failure: a novel approach to its pathogenesis and treatment , 2002, European journal of heart failure.

[96]  M. Pfeffer,et al.  Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. , 2002, Journal of the American College of Cardiology.

[97]  D. Mann,et al.  Angiotensin II Induces Tumor Necrosis Factor Biosynthesis in the Adult Mammalian Heart Through a Protein Kinase C-Dependent Pathway , 2002, Circulation.

[98]  K. Dickstein,et al.  Effect of aerobic exercise training on plasma levels of tumor necrosis factor alpha in patients with heart failure. , 2001, The American journal of cardiology.

[99]  A. Cohen-Solal,et al.  Physical training in patients with chronic heart failure enhances the expression of genes encoding antioxidative enzymes. , 2001, Journal of the American College of Cardiology.

[100]  J. Dwight,et al.  Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[101]  A. Coats,et al.  Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. , 2001, European heart journal.

[102]  V. Hasselblad,et al.  Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. , 2001, American heart journal.

[103]  C. Long.  The Role of Interleukin-1 in the Failing Heart , 2001, Heart Failure Reviews.

[104]  G. Dehmer,et al.  Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. , 2001, American heart journal.

[105]  S. Nitter‐Hauge,et al.  Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure , 2001, Circulation.

[106]  S. Anker,et al.  Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.

[107]  M. Daha,et al.  Is the proximal tubular cell a proinflammatory cell? , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[108]  G. Dibona.  Nervous kidney. Interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function. , 2000, Hypertension.

[109]  M. Kinoshita,et al.  High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. , 2000, Journal of the American College of Cardiology.

[110]  James T. Willerson,et al.  Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.

[111]  P. Stenvinkel,et al.  Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[112]  G. Freeman,et al.  beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. , 2000, Circulation.

[113]  M. Kinoshita,et al.  Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. , 2000, Journal of the American College of Cardiology.

[114]  S. Frøland,et al.  Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. , 1999, Journal of the American College of Cardiology.

[115]  Josef Niebauer,et al.  Endotoxin and immune activation in chronic heart failure: a prospective cohort study , 1999, The Lancet.

[116]  R. Belardinelli,et al.  Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. , 1999, Circulation.

[117]  Aroon D. Hingorani,et al.  Acute Systemic Inflammation Impairs Endothelium-Dependent Dilatation in Humans , 1999, Circulation.

[118]  S. Frøland,et al.  Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1999, The American journal of cardiology.

[119]  T. LeJemtel,et al.  Sustained improvement in flow-mediated vasodilation after short-term administration of dobutamine in patients with severe congestive heart failure. , 1999, Circulation.

[120]  StephanGielen,et al.  Regular Physical Exercise Corrects Endothelial Dysfunction and Improves Exercise Capacity in Patients With Chronic Heart Failure , 1998 .

[121]  S. Keteyian,et al.  Exercise training in heart failure. , 1998, Progress in cardiovascular diseases.

[122]  M. Reale,et al.  Serum Levels of Soluble Adhesion Molecules in Chronic Renal Failure and Dialysis Patients , 1998, Nephron.

[123]  F. Clubb,et al.  Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.

[124]  D. Fukai,et al.  Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. , 1998, Journal of the American College of Cardiology.

[125]  C. Holt,et al.  Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. , 1998, Journal of molecular and cellular cardiology.

[126]  L. Lind,et al.  Proinflammatory cytokines, measured in a mixed population on arrival in the emergency department, are related to mortality and severity of disease , 1997, Journal of internal medicine.

[127]  A. Koretsky,et al.  Dilated Cardiomyopathy in Transgenic Mice With Cardiac-Specific Overexpression of Tumor Necrosis Factor-α , 1997 .

[128]  P. Poole‐Wilson,et al.  Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. , 1997, The American journal of cardiology.

[129]  W. Edwards,et al.  Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. , 1997, Circulation.

[130]  K. H. Kim,et al.  Effects of TNF-alpha on [Ca2+]i and contractility in isolated adult rabbit ventricular myocytes. , 1996, The American journal of physiology.

[131]  T. LeJemtel,et al.  Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. , 1996, Journal of the American College of Cardiology.

[132]  H. Oral,et al.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.

[133]  M. Munger,et al.  Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1996, The American journal of cardiology.

[134]  H. Drexler,et al.  Physical training improves endothelial function in patients with chronic heart failure. , 1996, Circulation.

[135]  D. Fukai,et al.  Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. , 1995, The American journal of cardiology.

[136]  O. Febo,et al.  Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. , 1995, Circulation.

[137]  E. Imai,et al.  Angiotensin II stimulates interleukin-6 release from cultured mouse mesangial cells. , 1995, Journal of the American Society of Nephrology : JASN.

[138]  P. Jungers,et al.  Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. , 1995, Journal of immunology.

[139]  B. Pereira,et al.  Plasma levels of IL-1β, TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients , 1994 .

[140]  J. McMurray,et al.  Evidence of oxidative stress in chronic heart failure in humans. , 1993, European heart journal.

[141]  J. C. Romero,et al.  Renal effects of angiotensin II inhibition during increases in renal venous pressure. , 1992, Hypertension.

[142]  S. Favilla,et al.  Vascular Renin‐Angiotensin System and Neurotransmission in Hypertensive Persons , 1991, Hypertension.

[143]  G. Habermehl,et al.  Interleukin 1-α and tumor necrosis factor-α induce oxygen radical production in mesangial cells , 1990 .

[144]  V. Kon,et al.  Role of renal sympathetic nerves in mediating hypoperfusion of renal cortical microcirculation in experimental congestive heart failure and acute extracellular fluid volume depletion. , 1985, The Journal of clinical investigation.

[145]  J. Hall,et al.  Renal hemodynamic responses to increased renal venous pressure: role of angiotensin II. , 1982, The American journal of physiology.

[146]  H. F. Wood,et al.  A study of C-reactive protein in the serum of patients with congestive heart failure. , 1956, American heart journal.

[147]  A. Voors.  [The value of physical training in patients with heart failure]. , 2009, Nederlands tijdschrift voor geneeskunde.

[148]  R. Kunz,et al.  Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the ReninAngiotensin System on Proteinuria in Renal Disease , 2008, Annals of Internal Medicine.

[149]  M. Elahi,et al.  NO-cGMP and TNF-alpha counter regulatory system in blood: understanding the mechanisms leading to myocardial dysfunction and failure. , 2007, Biochimica et biophysica acta.

[150]  K. Johansen.  Exercise and Chronic Kidney Disease , 2005, Sports medicine.

[151]  P. Doevendans,et al.  Renal function; , 2004 .

[152]  H. Drexler,et al.  Chronic heart failure and proinflammatory cytokines: possible role of physical exercise. , 2004, Exercise immunology review.

[153]  F. Gesek,et al.  Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. , 2003, American journal of physiology. Renal physiology.

[154]  M. Daha,et al.  Interleukin 6 production by human proximal tubular epithelial cells in vitro: analysis of the effects of interleukin-1α (IL-1α) and other cytokines , 1994 .